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Purpose or Objective: Purpose: To analyze feasibility and 
toxicity of radical hypofractionated RT schedules in elderly 
patients with NSCLC 
 
Material and Methods: Material and methods: Elderly 
patients (≥70 years old) affected by stage III inoperable 
NSCLC were treated in our institution with radical IMRT 
(VMAT RA) according to moderately hypofractionated 
schedules: 56 Gy/20 fractions or 55 Gy/22 fractions or 50 
Gy/20 fractions depending on dose constraints of adjacent 
organs at risk. Patients underwent simulation CT in supine 
position, immobilized with a thermoplastic mask. PET CT was 
performed for simulation and coregistered with CT. Primary 
end point of this analysis were acute and late toxixcities, 
secondary end points were local control and overall survival. 
 
Results: Results: 41 patients, treated between January 2013 
and April 2015, were included in this analysis. Mean age was 
78.59 years (range 70-86). 22 patients were staged IIIA, 19 
patients IIIB. All but one patients had pathological nodal 
involvement (N1:5, N2: 24, N3: 11). Most of patients were 
unsuitable for chemotherapy for comorbidities and poor 
general conditions. 15 patients received chemotherapy 
before RT, concomitant RT-CHT was not allowed. Acute G1-2 
toxicity was recorded in 25 patients(61), mostly esophagitis, 
dyspnea and dry cough. Late toxicity was recorded in 13 
patients, the most reported side effects were pneumonitis 
and dyspnea. No G3 or G4 acute or late toxicity were 
recorded. A complete response was obtained in two patients, 
26 showed a partial response, while progressive disease was 
recorded in 2 cases. At time of analysis, with a mean follow 
up of 9.89 months (range 1.08-25.43), 17 patients died for 
disease progression, one patient died for other causes, 8 
patients were alive with distant metastases and 15 were alive 
without distant progression. Actuarial OS at 1 and 2 years 
were 51.3% and 35.1% respectively. Mean estimated OS was 
15.12 months (range 12.02-18.22). Actuarial local control at 1 
and 2 years were 72%. 10 patients experienced local 
progression. Mean estimated LC was 12.4 months (range 9.6-
15.1). 
 
Conclusion: Conclusion: Radical hypofractionated IMRT 
(VMAT RA) is a valid treatment for locally advanced 
inoperable NSCLC in elderly frail patients . Our study shows 
that this approach is safe and feasible also in a fragile elder 
population. Survival data are satisfactory. 
 
EP-1444  
Short-course accelerated palliative radiation therapy for 
advanced solid cancers in elderly patients 
L. Caravatta
1Centro di Radioterapia e Medicina Nucleare- P.O. Businco, 
Radiotherapy Unit, Cagliari, Italy 
1, G. Torre2, F. Deodato2, J. Capuccini3, A. 
Farioli4, M. Buwenge3, G. Macchia2, S. Manfrida5, S. Cilla6, S. 
Mignogna7, W. Tigneh8, A.F.M.K. Uddin9, T. Salah10, D. 
Dawotola11, P.A. Banu12, M. Moroni13, M. Pieri3, A. Arcelli3, F. 
Bertini3, S. Cammelli3, V. Valentini5, A.G. Morganti3 
2Fondazione di Ricerca e Cura “Giovanni Paolo II”-Catholic 
University of Sacred Heart, Radiotherapy Unit, Campobasso, 
Italy 
3Radiation Oncology Center- S. Orsola-Malpighi Hospital- 
University Of Bologna, Department of Experimental-
Diagnostic and Specialty Medicine-DIMES, Bologna, Italy 
4S. Orsola-Malpighi Hospital- University Of Bologna, 
Department of Medical and Surgical Sciences-DIMEC, 
Bologna, Italy 
5Policlinico Universitario "A. Gemelli" - Catholic University of 
Sacred Heart, Department of Radiotherapy, Roma, Italy 
6Fondazione di Ricerca e Cura “Giovanni Paolo II”-Catholic 
University of Sacred Heart, Medical Physics Unit, 
Campobasso, Italy 
7Fondazione di Ricerca e Cura “Giovanni Paolo II”-Catholic 
University of Sacred Heart, General Oncology Unit, 
Campobasso, Italy 
8Black Lion Hospital, Department of Radiotherapy, Addis 
Ababa, Ethiopia 
9United Hospital Limited, Radiation Oncology Department, 
Gulsha- Dhaka, Bangladesh 
10Assiut University, Faculty of Medecine, Assiut, Egypt 
11Radiotherapy and Oncology Center, Department of 
Radiotherapy, Abuth- Zaria, Nigeria 
12Delta Medical Center, Radiation Oncology Department, 
Dhaka, Bangladesh 
13Fondazione Seragnoli, Hospice Bentivoglio, Bologna, Italy 
 
Purpose or Objective: To assess the efficacy and safety of a 
SHort-course Accelerated RadiatiON therapy (SHARON) 
regimen in the palliative treatment of locally advanced or 
metastatic cancers in elderly patients.  
 
Material and Methods: Eligibility criteria of this analysis 
(pooled analysis of 3 phase II studies) were: patients with 
histologically confirmed solid cancers, age ≥ 80 years, 
patients with an expected survival > 3 months and Eastern 
Cooperative Oncology Group (ECOG) performance status of ≤ 
3. The primary endpoint was to evaluate the symptoms 
response rate produced by a radiotherapy regimen based on 
the delivery of 4 radiotherapy fractions (5 Gy per fraction) 
with a twice daily fractionation in two consecutive days 
 
Results: Twenty-four patients were included in this analysis. 
Characteristics of the patients were: male/female: 17/7; 
median age: 87.0 years (range: 80-98). ECOG performance 
status was < 3 in 16 patients (66.7%). Six patients (25.0%) had 
locally advanced thoracic cancers, 13 patients (54.2%) had 
advanced primary or metastatic H&N tumors and 5 patients 
(20.8%) had complicated bone metastases. With a median 
follow-up time of 5.0 months (range, 1 to 8 months), eleven 
G1-G2 acute skin (45.9%) and G1-2 mucositis (12.5%) 
toxicities were recorded. One patient (4.2%) experienced G1 
acute gastro-intestinal toxicity and only 1 patient (4.2%) 
experienced G3 acute mucositis. Of 24 symptomatic patients, 
19 showed an improvement or resolution of baseline 
symptoms (overall palliative response rate: 79.2%). Three-
months overall survival was 89.7% (median survival time: 7.0 
months; 95%CI 5.4-8.6 mo). Median survival without 
symptoms progression was 5.0 months (95%CI: 2.5-7.5 mo). In 
23 patients with pain, a significant reduction of this symptom 
was recorded in terms of VAS (mean baseline VAS vs mean 
VAS after treatment: 3.9 versus 1.7, p=0.001).  
 
Conclusion: Short-course accelerated radiotherapy in locally 
advanced or metastatic cancers is effective in terms of 
symptom relief and well tolerated even in older patients. 
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Purpose or Objective: The optimal treatment of bladder 
cancer has been a subject of continuous controversy. In North 
America, as well as in Europe, the radical cistectomy as the 
standard option for invasive bladder cancer. In the western 
countries the elderly ones constitute the part of the 
population in more rapid growth and, insofar, the group to 
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taller risk to develop a cancer. The elderly patients, because 
of the presence of concomitant pathologies, they set to the 
clinician particular problems and limitations in the 
therapeutic planning. Several groups have reported the value 
of combination of conservative surgery and 
radiochemotherapy or radical radiotherapy alone in patients 
affected by bladder cancer. In this study we have 
retrospectively analyzed the prognostic factors influencing 
survival and relapse free-survival after radiotherapy following 
transurethral resection (TURB) for bladder cancer.  
 
Material and Methods: Between May 2013 and December 
2014, 33 patients with bladder cancer have been treated at 
the Operative Unity of Radiotherapy and Radiobiology, 
Hospital of Catanzaro. Of these, 19 patients were treated 
with radiotherapy alone (RT) and nine with platin based 
radio-chemotherapy (RCT) after TURB. Overall survival (OS) 
and Relapse-Free Survival (RFS) were analyzed with the 
Kaplan and Meyer methods. Comparisons were made using 
the log-rank test. In the analysis, we proposed the following 
prognostic factors as affecting the development of relapse 
after initial treatment: Univariate analysis was performed for 
age, grade, R-status after initial TURB, T-category relevant 
to the endpoints initial response, survival and bladder 
preservation. 
 
Results: Median age was 78 years (range 66-90 years), while 
the median follow-up is 15 months (range 5-42 months). All 
patients were treated with three-dimensional conformal 
therapy (3D-CRT). The total dose of radiotherapy ranged 
5040 cGy to 6000 cGy. Complete remissions were achieved at 
57% after RT and TURB. Toxicity was acceptable. Further 
significant prognostic factors were pT-category and R-status. 
For all patients survival was 31% after 2 years and 25% at 4 
years, while the relapse-free survival rates were 19% and 15% 
at 2 and 4 years, respectively. In the univariate analysis the 
only significant factor for survival and relapse-free survival 
and bladder preservation was the R-status after initial TURB 
 
Conclusion: In conclusion, treatment of bladder cancer by 
TURB and RT alone is an alternative to primary cystectomy, 
for the elderly patients. Initial TURB is recommended to be 
as radical as possible. 
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Purpose or Objective: to compare 2 multifraction 
radiotherapy (RT)schedules in the palliation of painful bone 
metastases in elderly patients, assessed at baseline with the 
Cumulative Illness Rating Scale for Geriatrics (CIRS-G). 
 
Material and Methods: 132 elderly patients were analyzed. 
Seventy-seven patients received a single 8Gy in single 
fraction and 55 received 20 Gy in 5 fractions. The choice of 
the treatment schedule was related to comorbidity, 
disability, target size and compliance. Pain intensity was 
measured with Numeral Rating Scale (NRS: 0 = no pain; 10 = 
high pain). Complete response was defined a pain reduction > 
3 of three points, partial response as a pain reduction ≥2 (2 ≤ 
pain reduction ≤ 3), no response was defined by pain score < 
2. Pain evaluation was recorded at baseline and at 1-4-8 
weeks after completing RT. 
 
Results: overall response: 90.3% in 8 Gy arm (49.8% complete 
and 40.5% partial), 94.6% in 20 Gy arm (44.6% complete and 
50%partial). No high grade toxicity were reported. The relief 
of pain was attained faster with single fraction (p-value ~ 
0.2). We observed maximum response of pain control after 8 
weeks and no significant differences were noted between 
two groups. The re-treatment rate was 17.6% vs 11.1% 
respectively. 
 
Conclusion: no significant differences between the two arms 
in terms of pain response, pain control and toxicity. Our 
experience showed that not influenced by age, but in the 
elderly, life expectancy, comorbidities evaluated with the 
CIRS-G, and compliance, are crucial in selecting of shorter 
treatment. 
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Purpose or Objective: To evaluate stereotactic body 
radiation therapy (SBRT) for oligometastatic lung tumors in 
patients 75 years old or older. 
 
Material and Methods: Between 2002 and 2015, 24 elderly 
patients with 34 lung metastases were treated using SBRT at 
our institution. SBRT procedure involved: Slow-scan 
computed tomography (CT) simulation with immobilization 
devices, contouring the target volume in 3 sets of CTs, 
superimposing the volumes in the planning system to 
represent the internal target volume and dose calculation 
using heterogeneity correction. Radiation delivery with 
multiple static planar or non-coplanar beams and arc therapy 
assured conformal dose distribution and steep fall-off of the 
radiation. The prescribed dose was 3 fractions of 15 Gy each 
(90%) given in 6-10 days or a single 30-Gy fraction (10%), with 
at least 95 % of the ITV covered by the 95% isodose line. 
Dosimetric constraints were set for surrounding organs at 
risk. Repeated cone-beam CT were used to verify daily 
positioning. Toxicity and radiologic response were assessed in 
follow-up, using standardized criteria (RTOG and RECIST) and 
analyzed retrospectively. Survival rates and toxicities were 
calculated by the Kaplan-Meier method. 
 
Results: Median patient age was 79 years (75-85). The origin 
of the metastases was: non-small cell lung cancer (53 %), 
colorectal adenocarcinoma (24 %), urotelial tumors (8.5 %), 
thyroid carcinoma (8.5 %), endometrial adenocarcinoma (3%) 
and parotid tumor (3%). All patients had good performance 
status at the moment of treatment (ECOG PS 0-1). Fifty-six 
percent of all patients also received systemic treatment 
before or after SBRT. Mean tumor volume was 10.7 cm3 (0.5-
106). The only acute toxicity reported was rib pain, grade 2, 
in 1 patient. No grade > 3 acute or any chronic toxicities 
were identified. The median follow-up was 11 months (1-60). 
The 6, 12 and 18 month overall survivals were 97, 88 and 85 
%. Local control in the irradiated volume is 97 %, the only 
failure occurring in a patient who also had distal progression 
from colon adenocarcinoma. 
 
Conclusion: SBRT is an excellent treatment option for lung 
oligometastasis in elderly patients. Our encouraging results 
are in line with those reported in recent literature for 
younger patients.  
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Purpose or Objective: Some recent data has questioned the 
impact of larynx preservation strategy on overall survival. 
The median age of patients in most major larynx preservation 
trials was 55-60 years with little representation of the older 
age group. The aim of this study is to review the tolerance 
and outcomes of larynx preservation treatment in the older 
population (≥ 65). 
 
